Skip to search formSkip to main contentSkip to account menu

MAGE-3.A1 Peptide Vaccine

Known as: HLA-A1-Restricted MAGE-3 Peptide Vaccine, MAGE-3.A1 
A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3… 
National Institutes of Health

Related topics

Related topics

1 relation
Antigen Sensitization

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Immunization of melanoma patients with a MAGE-3 peptide combined with IFNa.
2606 Background: Melanoma patients with lymph node metastasis at diagnosis have a less than 60% survival rate at 5 years… 
1998
1998
Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.
T cells infiltrating pre- and postvaccine metastases obtained from melanoma patients vaccinated with either dinitrophenyl (DNP… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)